肿瘤细胞治疗研究
英文原题：The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
经典霍奇金淋巴瘤的治疗格局在过去十年中发生了巨大变化。
经典霍奇金淋巴瘤的治疗格局在过去十年中发生了巨大变化。维布妥昔单抗（BV）和检查点抑制剂（CPI）等复发和难治性主要治疗药物正在被前移至更早的治疗线。然而，对于在BV和CPI治疗后进展的患者的治疗仍然是一个挑战。异基因干细胞移植在这一患者群体中仍然发挥着重要作用，因为它是目前唯一具有治愈潜力的治疗方法。遗憾的是，并非所有患者都适合移植，而且许多患者之后仍会复发。细胞毒性化疗和放疗可用于症状姑息治疗或作为移植的桥接。靶向治疗，包括抗体药物偶联物camidanlumab tesirine，以及转录类药物如哺乳动物雷帕霉素靶蛋白和组蛋白去乙酰化酶抑制剂，已在难治性疾病患者中显示出一定潜力。此外，CPI与新型药物的联合治疗可能有助于克服治疗耐药。细胞治疗的临床试验，包括靶向CD30的CAR-T 细胞和异基因NK 细胞联合AFM13（一种CD30/CD16a双特异性抗体），已显示出令人鼓舞的结果。人们迫切期待这一患者群体能有更多的治疗选择。
The treatment landscape of classical Hodgkin lymphoma has changed dramatically over the past decade. Relapsed and refractory mainstay therapeutics such as brentuximab vedotin (BV) and checkpoint inhibitors (CPIs) are being moved to earlier lines of therapy. However, the treatment of patients who progress after BV and CPI remains a challenge. Allogeneic stem cell transplantation still plays an important role in this patient population as the only current treatment approach with curative potential. Unfortunately, not all patients are transplant candidates, and many will still relapse afterward. Cytotoxic chemotherapy and radiation may be used for symptom palliation or as a bridge to transplant. Targeted therapies, including the antibody drug conjugate, camidanlumab tesirine, and transcriptional agents such mammalian target of rapamycin and histone deacetylase inhibitors have shown some potential in patients with refractory disease. In addition, combination therapies with CPIs and novel agents may help overcome resistance to therapy. Clinical trials with cellular therapies, including chimeric antigen receptor T cells targeting CD30 and allogeneic natural killer cells combined with AFM13, a CD30/CD16a-bispecific antibody, have shown promising results. The availability of more therapeutic options for this patient population is eagerly awaited.
MEMBER ACCOUNT
登录成功会直接打开下一页。
